Hydroxychloroquine and QTc
Zeile 2: | Zeile 2: | ||
{{qt|Hydroxychloroquine}} | {{qt|Hydroxychloroquine}} | ||
+ | ---- | ||
+ | hcq can prolongate qtc like longQT syndrome causing torsade de pointes potentially lethal cardiac electrical storm. beyond showing the papers, i set up the question whether concomitant magnesium substitution could prevent this thus making hcq safer. no explicit data available, beyond the traditional post-event administration of 2-4 grams mgso4 i.v. | ||
+ | ---- | ||
{{bibi|TI=HCQ - QTc|S1=chloroquine+OR+hydroxychloroquine|S2=QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG|S3=|dPMID=08/05/20|dPMC=08/05/2020}} | {{bibi|TI=HCQ - QTc|S1=chloroquine+OR+hydroxychloroquine|S2=QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG|S3=|dPMID=08/05/20|dPMC=08/05/2020}} | ||
Zeile 594: | Zeile 597: | ||
{{tp|p=32907357|t=2020. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.|pdf=|usr=019}} | {{tp|p=32907357|t=2020. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.|pdf=|usr=019}} | ||
{{tp|p=32918829|t=2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.|pdf=|usr=019}} | {{tp|p=32918829|t=2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.|pdf=|usr=019}} | ||
+ | {{tp|p=32921678|t=2020. Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32936259|t=2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.|pdf=|usr=019}} | ||
+ | {{tp|p=32956782|t=2020. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.|pdf=|usr=019}} | ||
+ | {{tp|p=32956851|t=2020. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.|pdf=|usr=019}} | ||
+ | {{tp|p=32958120|t=2020. Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.|pdf=|usr=019}} | ||
+ | {{tp|p=32964535|t=2020. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.|pdf=|usr=019}} | ||
+ | {{tp|p=32964653|t=2020. Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic.|pdf=|usr=019}} | ||
+ | {{tp|p=32971536|t=2020. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.|pdf=|usr=019}} | ||
+ | {{tp|p=33030660|t=2020. QTc interval prolongation, COVID-19 and chloroquine.|pdf=|usr=020}} | ||
+ | {{tp|p=33032282|t=2020. Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.|pdf=|usr=020}} | ||
+ | {{tp|p=33044166|t=2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.|pdf=|usr=020}} | ||
+ | {{tp|p=33047848|t=2020. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.|pdf=|usr=020}} | ||
+ | {{ttp|p=33059567|t=2020. Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33063447|t=2020. QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study.|pdf=|usr=020}} | ||
+ | {{ttp|p=33075484|t=2020. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33077410|t=2020. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.|pdf=|usr=020}} | ||
+ | {{tp|p=33089050|t=2020. Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.|pdf=|usr=020}} | ||
+ | {{tp|p=33098839|t=2020. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.|pdf=|usr=020}} | ||
+ | {{tp|p=33102533|t=2020. QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment.|pdf=|usr=020}} | ||
+ | {{tp|p=33132915|t=2020. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.|pdf=|usr=020}} | ||
+ | {{tp|p=33154498|t=2020. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.|pdf=|usr=020}} | ||
+ | {{ttp|p=33163895|t=2020. The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33164544|t=2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33164789|t=2020. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33173848|t=2020. Hydroxychloroquine and QT prolongation: reassuring data in approved indications.|pdf=|usr=023}} | ||
+ | {{ttp|p=33192602|t=2020. Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin.|pdf=|usr=020}} | ||
+ | {{tp|p=33240503|t=2020. Electrical storm in a patient with COVID-19 treated with hydroxychloroquine: A case report.|pdf=|usr=021}} | ||
+ | {{tp|p=33280207|t=2020. Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID-19.|pdf=|usr=022}} | ||
+ | {{tp|p=33282067|t=2020. Electrocardiogrammes d un patient COVID-19 traite par l association hydroxychloroquine et azithromycine.|pdf=|usr=022}} | ||
+ | {{tp|p=33291194|t=2020. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.|pdf=|usr=022}} | ||
+ | {{tp|p=33307378|t=2020. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.|pdf=|usr=023}} | ||
+ | {{tp|p=C7212241|t=2020. Hydroxychloroquine-associated QT interval prolongation.|pdf=|usr=015}} | ||
+ | {{tp|p=C7237942|t=2020. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.|pdf=|usr=015}} | ||
+ | {{tp|p=C7289101|t=?. QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019.|pdf=|usr=015}} | ||
+ | {{tp|p=C7302795|t=2020. Bréve : Chloroquine OTC : danger !|pdf=|usr=015}} | ||
+ | {{tp|p=C7303435|t=2020. Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7317079|t=2020. Hydroxychloroquine: QTc prolongation: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7320242|t=?. Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint.|pdf=|usr=015}} | ||
+ | {{tp|p=C7334107|t=2020. Azithromycin/hydroxychloroquine: QT prolongation with a notched broad T-wave following off-label therapy: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7334118|t=2020. Hydroxychloroquine: Corrected QT interval prolongation first degree atrioventricular block and left bundle branch block during an off-label treatment with hydroxychloroquine for COVID-19 pneumonia: 3 case reports.|pdf=|usr=015}} | ||
+ | {{tp|p=C7334124|t=2020. Azithromycin/hydroxychloroquine/propofol: Hypoglycaemia and cardiotoxicities following off label use: 2 case reports.|pdf=|usr=015}} | ||
+ | {{tp|p=C7334127|t=2020. Hydroxychloroquine: QTc prolongation following off-label-use: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7648208|t=2020. Hydroxychloroquine: Borderline prolongation of QTc interval during off-label treatment: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7648225|t=2020. Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports.|pdf=|usr=023}} | ||
+ | {{tp|p=C7648240|t=2020. Hydroxychloroquine: QTc-prolongation following an off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7648244|t=2020. Hydroxychloroquine: QTc prolongation following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7677429|t=2020. Azithromycin/hydroxychloroquine: Cardiac disorder followed by off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7677447|t=2020. Azithromycin/hydroxychloroquine: Torsade-de-pointes following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7692421|t=2020. Azithromycin/hydroxychloroquine: Torsades-de-pointes following off label treatment: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7692436|t=2020. Hydroxychloroquine: Prolonged QTc interval following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7717273|t=?. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.|pdf=|usr=023}} | ||
+ | {{tp|p=C7726269|t=2020. Ceftriaxone/hydroxychloroquine/tocilizumab: QT prolongation torsade-de-pointes and off label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7726274|t=2020. Azithromycin/hydroxychloroquine: Prolonged corrected QT following off label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7728508|t=2020. Hydroxychloroquine: Electrical storm and QT interval prolongation following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7728516|t=2020. Chloroquine/erythromycin: QT interval prolongation and Torsade de Pointes: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7728522|t=2020. PRAC review confirms chloroquine- and hydroxychloroquine-related AEs.|pdf=|usr=023}} | ||
+ | {{tp|p=C7654303|t=?. HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.|pdf=|usr=023}} |
Version vom 11. April 2021, 15:36 Uhr
Hydroxychloroquine |
hcq can prolongate qtc like longQT syndrome causing torsade de pointes potentially lethal cardiac electrical storm. beyond showing the papers, i set up the question whether concomitant magnesium substitution could prevent this thus making hcq safer. no explicit data available, beyond the traditional post-event administration of 2-4 grams mgso4 i.v.
HCQ - QTc
- THIS chloroquine+OR+hydroxychloroquine
- AND QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG
- NOT
- PubMed: 08/05/20 PMCentral: 08/05/2020
- search on moremed.org
32383430 2020. Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with COVID-19 Treated with Hydroxychloroquine.
22391528 2012. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.
32354666 2020. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.
32331979 2020. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
32638906 2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.
30835490 2019. Electrophysiological and Pharmacological Characterization of Human Inwardly Rectifying Kir2.1 Channels on an Automated Patch-Clamp Platform.
22369270 2012. QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.
30400791 2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.
22987900 2012. Severe primary hypothyroidism presenting with torsades de pointes.
23203174 2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.
32350872 2020. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
23701202 2013. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.
32299753 2020. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
32686633 2020. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.
21233253 2011. Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine.
27478650 2016. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine.
19710529 2009. Chloroquine blocks a mutant Kir2.1 channel responsible for short QT syndrome and normalizes repolarization properties in silico.
32347743 2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
32588427 2020. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
32285930 2020. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
32626630 2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
32605683 2020. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas.
32372695 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
32356580 2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
20585026 2010. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets.
31827438 2019. The Antimalarial Chloroquine Reduces the Burden of Persistent Atrial Fibrillation.
32387247 2020. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019.
32380291 2020. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
32479900 2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.
32407884 2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
32438018 2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
32610165 2020. Effects of hydroxychloroquine treatment on QT interval.
32622993 2020. Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk.
32621881 2020. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.
32302703 2020. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32363145 2020. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.
24958937 2014. Ciprofloxacin-Induced Syndrome of Inappropriate Antidiuretic Hormone; Anaphylactic Shock Due to Thrombolytic Administration; Hydroxychloroquine-Induced QT-Interval Prolongation; Complex Regional Pain Syndrome After Tetanus Toxoid Injection.
32278018 2020. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.
32621997 2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?
32621996 2020. HCQ induced QT prolongation- Primum non nocere.
32534189 2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
32439366 2020. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
32623082 2020. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
32624690 2020. Cardiovascular disease management during the coronavirus disease 2019 pandemic.
32627127 2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
32283123 2020. Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
32407770 2020. COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.
32463348 2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
32463308 2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
11960982 2002. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
32753328 2020. Torsades de Pointes in Coronavirus Disease 2019 Infection.
32485061 2020. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin.
32549293 2020. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.
32731139 2020. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19.
27173501 2016. Quinine and the ABCs of Long QT: A Patient's Misfortune with Arthritis, (Alcoholic) Beverages, and Cramps.
32474031 2020. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
32418181 2020. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
32494896 2020. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
19285083 2009. Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome.
23759957 2013. Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models.
32392282 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
32356863 2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
26818020 2016. Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.
32359771 2020. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
32442941 2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.
32511528 2020. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions.
32648153 2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.
32643072 2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.
32350818 2020. Chloroquine-induced QTc prolongation in COVID-19 patients.
29290967 2017. Modelling the effects of chloroquine on KCNJ2-linked short QT syndrome.
32654931 2020. Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19.
17213921 2007. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers.
32701969 2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
11320287 2001. Recurrent syncope. Drug induced long QT syndrome.
32441496 2020. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
18216262 2008. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel.
32327397 2020. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
32501367 2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.
32694915 2020. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen.
32457932 2020. Chloroquine, hydroxychloroquine and COVID-19.
32503662 2020. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
32493478 2020. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
32493468 2020. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
32736597 2020. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
32616063 2020. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
32665039 2020. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.
32395788 2020. Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series.
17984356 2007. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig.
12363064 2002. The effects of antimalarial drugs on ventricular repolarization.
31907183 2020. High-Dose Chloroquine for Uncomplicated Plasmodium falciparum Malaria Is Well Tolerated and Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children.
32523150 2020. Potenciales efectos pro-arritmicos de la farmacoterapia contra SARS-CoV-2.
8267504 1993. Les tachycardies ventriculaires d'origine medicamenteuse.
30738635 2019. Fetal dysrhythmias.
18182162 2008. Lysosome mediated Kir2.1 breakdown directly influences inward rectifier current density.
32687645 2020. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
32267732 2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
16615675 2006. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.
30441573 2018. Computational Analysis of the Action of Chloroquine on Short QT Syndrome Variant 1 and Variant 3 in Human Ventricles.
28216048 2017. Chloroquine blocks the Kir4.1 channels by an open-pore blocking mechanism.
14729380 2004. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.
32693652 2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
16352079 2002. Antimalarial drugs inhibit the acetylcholine-receptor-operated potassium current in atrial myocytes.
23409733 2013. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement.
17590456 2008. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.
3183189 1988. Protective cardiovascular effects of diazepam in experimental acute chloroquine poisoning.
32750131 2020. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
32700555 2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
23872551 2013. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus.
25654185 2015. Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.
32534369 2020. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
19654266 2009. Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.
7629906 1995. The hazards of chloroquine self prescription in west Africa.
31776555 2020. Drug interactions with antimalarial medications in older travelers: a clinical guide.
32356857 2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
24360369 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
17646028 2007. Cardiotoxicity of antimalarial drugs.
32706953 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
32488217 2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
12494620 2002. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers.
23192368 2013. Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine.
21125143 2010. Arrhythmias in systemic lupus erythematosus.
PMC
21615117 2011. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133.
23685953 2013. Inside job: ligand-receptor pharmacology beneath the plasma membrane.
32517786 2020. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
29937880 2017. QTc prolongation in Black diabetic subjects with cardiac autonomic neuropathy.
32497913 2020. A current review of COVID-19 for the cardiovascular specialist.
32624192 2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
32425199 2020. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
25006531 2014. Gold nanoparticle-spermidine complex blocks the inward rectifier potassium channel.
32737841 2020. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
32336586 2020. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
24731243 2014. Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation.
32247318 2020. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
32425051 2020. Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.
32232419 2020. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
24597863 2014. Assessment of inhomogeneities of repolarization in patients with systemic lupus erythematosus.
16699058 2006. Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis.
22615288 2012. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.
32571633 2020. Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.
32675039 2020. Hydroxychloroquine and Potential Drug Interactions in Older Adults.
32354666 2020. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.
32740801 2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
31463053 2019. British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication.
22364570 2012. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus.
32446195 2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.
32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.
32664944 2020. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.
30400791 2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.
32409561 2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
32409486 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
32169926 2020. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.
28601826 2017. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.
32384171 2020. COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.
26183037 2016. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
23167578 2013. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.
20642543 2010. Drug- and non-drug-associated QT interval prolongation.
19076152 2009. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study.
16869820 2007. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.
12207642 2002. The significance of QT interval in drug development.
12207637 2002. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.
11966667 2002. Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems?
3741724 1986. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.
16474415 2006. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
15655517 2005. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.
12839862 2003. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
12839860 2003. Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.
29924137 2018. Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review.
32537248 2020. Mechanisms of Myocardial Injury in Coronavirus Disease 2019.
18651395 2008. Drug-induced spatial dispersion of repolarization.
32557011 2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.
32671601 2020. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
26351590 2015. Novel Therapies for Myocardial Irritability following Extreme Hydroxychloroquine Toxicity.
32123164 2020. Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
32629149 2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
27540685 2017. Styrax blocks inward and outward current of Kir2.1 channel.
26556552 2015. Cardiac ion channels.
23221912 2013. Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
32436730 2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
32434385 2020. Cardiac Arrhythmias in COVID-19 Infection.
23449547 2013. Rotors and the dynamics of cardiac fibrillation.
32228309 2020. Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association.
32442023 2020. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
20142454 2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
32438948 2020. Just the facts: What drugs are safe and effective for COVID-19?
32468425 2020. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
32533455 2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?
25572282 2015. Population-based study of QT interval prolongation in patients with rheumatoid arthritis.
29497521 2012. Episodic electrolyte disorders and renal failure due to a rare disease: the McKittrick-Wheelock syndrome.
26833512 2016. Sarcoidosis of the cardio-pulmonary systems.
32422406 2020. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
32306288 2020. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
32495226 2020. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
32268005 2020. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.
32401962 2020. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
32269021 2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
30962197 2019. Use of vitamin D drops leading to kidney failure in a 54-year-old man.
29957821 2018. Immunosuppressive treatment for proliferative lupus nephritis.
21328286 2011. Azithromycin for treating uncomplicated malaria.
32384908 2020. Chloroquine for COVID-19: rationale, facts, hopes.
32653015 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
32467423 2020. Potential mechanisms of cardiac injury and common pathways of inflammation in patients with COVID-19.
32626630 2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
32550090 2020. Bradycardia in Patients With COVID-19: A Calm Before the Storm?
32318865 2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.
24721648 2014. Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.
32395418 2020. An Update on Current Therapeutic Drugs Treating COVID-19.
24944403 2003. Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.
32417708 2020. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis."
31835542 2019. Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology.
32696429 2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
31844421 2019. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.
25749803 2015. Use of adjectives in abstracts when reporting results of randomized, controlled trials from industry and academia.
21468196 2010. A practical approach to genetic hypokalemia.
32369020 2020. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.
8617203 1996. Complementation between kinase-defective and activation-defective TGF-beta receptors reveals a novel form of receptor cooperativity essential for signaling.
32378805 2020. COVID-19 and toxicity from potential treatments: Panacea or poison.
32338155 2020. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
32562486 2020. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests.
24062937 2013. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review.
32347923 2020. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
32586646 2020. Electrocardiographic features of patients with COVID-19 pneumonia.
32553587 2020. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
32283298 2020. A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
32603692 2020. Current pharmacological treatments for SARS-COV-2: A narrative review.
32441761 2020. COVID-19 and QT interval prolongation: more than just drug toxicity?
26869865 2015. A systematic review of the cardiotoxicity of methadone.
32509013 2020. Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria.
21736423 2011. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.
25494485 2015. Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
32350928 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
29162702 2018. Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule.
32707160 2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.
32432127 2020. COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2.
26798623 2015. Long QT Syndrome: An Emerging Role for Inflammation and Immunity.
30294301 2018. Vitamin D Toxicity-A Clinical Perspective.
30532765 2018. FGF10 Protects Against Renal Ischemia/Reperfusion Injury by Regulating Autophagy and Inflammatory Signaling.
32733488 2020. Potential Fast COVID-19 Containment With Trehalose.
32733448 2020. Role of Autophagy in Lung Inflammation.
32574272 2020. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
29632529 2018. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?
32733907 2020. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.
32426364 2020. Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19.
32391371 2020. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.
32391370 2020. The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity.
31481873 2019. Hydrogen Sulfide Inhibits High Glucose-Induced Neuronal Senescence by Improving Autophagic Flux via Up-regulation of SIRT1.
31427967 2019. Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism.
29184497 2017. Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features.
31636573 2019. Enhancing Autophagy Diminishes Aberrant Ca(2+) Homeostasis and Arrhythmogenesis in Aging Rabbit Hearts.
29527175 2018. Cardiac Arrhythmias and Antiarrhythmic Drugs: An Autophagic Perspective.
25221519 2014. Inward rectifiers and their regulation by endogenous polyamines.
32615807 2020. Sudden cardiac death in COVID-19 patients, a report of three cases.
20543968 2010. Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.
32470824 2020. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement.
14594906 2003. Drug induced QT prolongation and torsades de pointes.
32387247 2020. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019.
32387246 2020. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.
32380291 2020. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
32479900 2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.
32470627 2020. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.
32407884 2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
32438018 2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
32244059 2020. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.
32585191 2020. COVID-19 and cardiac arrhythmias.
26025323 2015. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32695719 2020. Hydroxychloroquine in Dermatology and Beyond: Recent Update.
32534688 2020. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
32462545 2020. Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.
32389720 2020. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.
32305588 2020. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
32629115 2020. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
32738307 2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
32687949 2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.
32674929 2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
32205204 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
32565195 2020. Cardiac effects and toxicity of chloroquine: a short update.
32534189 2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32450198 2020. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
32194152 2020. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
32473921 2020. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
30222237 2018. Incidence and outcomes of long QTc in acute medical admissions.
24403843 2013. Antibiotics for the treatment of rheumatoid arthritis.
32738490 2020. The continued dilemma about usage of Hydroxychloroquine: Respite is in randomized control trials.
30805547 2018. Electrocardiographic disturbances in children with systemic lupus erythematosus.
32281213 2020. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
16984815 2006. Cell biology of membrane trafficking in human disease.
27803420 2016. Acquired Gitelman Syndrome in an Anti-SSA Antibody-positive Patient with a SLC12A3 Heterozygous Mutation.
20185054 2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
27957082 2014. Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation.
32270559 2020. Cardiac and arrhythmic complications in patients with COVID-19.
32282502 2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
7204500 1981. Fate of plasma membrane during endocytosis. III. Evidence for incomplete breakdown of immunoglobulin in lysosomes of cultured fibroblasts.
28425222 2017. Class III antiarrhythmic drugs amiodarone and dronedarone impair KIR 2.1 backward trafficking.
32397558 2020. Impact of COVID-19 on the Cardiovascular System: A Review.
29581800 2018. Impact of Drug Induced Long QT Syndrome: A Systematic Review.
26865283 2016. Safety Concerns Surrounding Quinolone Use in Children.
31656203 2019. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.
32622008 2020. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
27317161 2016. JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.
30515245 2018. Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge.
32494896 2020. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
22239221 2012. Rational approaches to improving selectivity in drug design.
32514696 2020. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.
32356252 2020. COVID-19: Therapeutics and Their Toxicities.
26159649 2016. A Literature Review of the Use of Sodium Bicarbonate for the Treatment of QRS Widening.
18072176 2007. Case files of the Drexel University Medical Toxicology Fellowship: methadone-induced QTc prolongation.
29438998 2018. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.
20498233 2010. A computational model of Purkinje fibre single cell electrophysiology: implications for the long QT syndrome.
10740988 2000. Antipsychotic agents and QT changes.
32642225 2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.
32363250 2020. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials.
32313885 2020. COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.
32363351 2020. Takotsubo Syndrome in the Setting of COVID-19 Infection.
32703574 2020. Multilead QT Screening Is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19 Era.
27042693 2016. STRUCTURAL AND FUNCTIONAL BASES OF CARDIAC FIBRILLATION. DIFFERENCES AND SIMILARITIES BETWEEN ATRIA AND VENTRICLES.
32356858 2020. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
32278373 2020. Regulators split on antimalarials for COVID-19.
32272080 2020. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.
31925317 2020. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
23864039 2013. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease.
28079193 2016. ECG non-specific ST-T and QTc abnormalities in patients with systemic lupus erythematosus compared with rheumatoid arthritis.
25881046 2015. Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study.
20003315 2009. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.
18613962 2008. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials.
21628620 2011. Antiparasitic therapy.
10885139 1999. Malaria in American troops in the South and Southwest Pacific in World War II.
29315692 2018. Comprehensive review of cardiovascular toxicity of drugs and related agents.
25010388 2014. HMGB1 in health and disease.
32316270 2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
29443946 2018. A Comparative Study of Human Saposins.
27869117 2016. Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells.
23389616 2013. Malaria biology and disease pathogenesis: insights for new treatments.
32690910 2020. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.
25533796 2015. Cardiorheumatology: cardiac involvement in systemic rheumatic disease.
19347024 2009. Diagnosis and management of the neurological complications of falciparum malaria.
32430617 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
32671650 2020. SARS-CoV-2/COVID-19: a primer for cardiologists.
29434902 2018. Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide.
23760395 2013. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling.
23759954 2013. Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo.
32550240 2020. Azithromycin Should Not Be Used to Treat COVID-19.
19030406 2007. A primer of paediatric toxic syndromes or 'toxidromes'
C7378994 2020. Azithromycin/hydroxychloroquine: Lengthening of the QT interval bradycardia and atrioventricular block following an off-label use: case report.
C7404419 ä. Communication missteps during COVIDâ€19 hurt those already most at risk.
C7334118 2020. Hydroxychloroquine: Corrected QT interval prolongation first degree atrioventricular block and left bundle branch block during an off-label treatment with hydroxychloroquine for COVID-19 pneumonia: 3 case reports.
C7334107 2020. Azithromycin/hydroxychloroquine: QT prolongation with a notched broad T-wave following off-label therapy: case report.
C7303435 2020. Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report.
C7290135 2020. QT interval prolongation with hydroxychloroquine plus azithromycin.
C7290151 2020. Risks of chloroquine or hydroxychloroquine use for COVID-19.
C7280102 ä. Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle.
C7300994 2020. Meeting the Challenge: Keen oversight and flexible operations keep manufacturers viable and productive despite daunting business conditions.
C7272317 2020. Hydroxychloroquine- and azithromycin-related heart disorders.
C7256915 2020. Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic.
C7257351 ä. Surface Treatments to Enhance the Functionality of PPEs.
C7212241 2020. Hydroxychloroquine-associated QT interval prolongation.
C7197234 2020. Safety concerns with higher dosage chloroquine in COVID-19 patients.
C7197245 2020. Antimalarial use in COVID-19 patients requires close monitoring.
C7262183 2020. NAATP on telemedicine and a ‘disease of isolation’.
C7148702 2016. Tourism economics and policy analysis: Contributions and legacy of the Sustainable Tourism Cooperative Research Centre.
22737589 2011. Fungal genome resources at NCBI.
29308119 2013. CONTROLLED DELIVERY OF ANTIANGIOGENIC DRUG TO HUMAN EYE TISSUE USING A MEMS DEVICE.
21630127 2011. AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development.
16353918 2005. Population pharmacokinetics/pharmacodynamics of anesthetics.
14621961 2003. Passive and iontophoretic transport enhancement of insulin through porcine epidermis by depilatories: Permeability and fourier transform infrared spectroscopy studies.
C7124145 ä. Hospital Systems Management.
25308141 2014. Using Publication Metrics to Highlight Academic Productivity and Research Impact.
22435868 2012. Optimizing Clinical Operations as part of a Global Emergency Medicine Initiative in Kumasi Ghana: Application of Lean Manufacturing Principals to Low Resource Health Systems.
20370740 2010. Improving Child Protection in the Emergency Department: A Systematic Review of Professional Interventions for Health Care Providers.
27779508 2016. “Staying in the Gameâ€: How Procedural Variation Shapes Competence Judgments in Surgical Education.
26505105 2015. Thresholds of Principle and Preference: Exploring Procedural Variation in Postgraduate Surgical Education.
25250744 2014. What’s Behind the Scenes? Exploring the Unspoken Dimensions of Complex and Challenging Surgical Situations.
23969352 2013. Understanding Clinical Uncertainty: What Is Going on When Experienced Surgeons Are Not Sure What to Do?
32010761 2020. Academic E-Mail Overload and the Burden of “Academic Spamâ€.
20074982 2010. Comparison between population average and experimentally measured Arterial Input Function in predicting biopsy results in prostate cancer.
19515584 2009. Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI.
32022555 2020. Single Atom Dynamics in Chemical Reactions.
21545881 2011. The influence of novel compliant floors on balance control in elderly women—A biomechanical study.
19353388 2009. Supervisor-Student Relations: Examining the Spectrum of Conflicts of Interest in Bioscience Laboratories.
16467894 2005. Databases of Discovery.
14594412 2003. Estrogen plus progestin did not improve health-related quality of life in postmenopausal women 50 to 79 years of age.
29637764 2018. Surface-Anchored Metal–Organic Framework–Cotton Material for Tunable Antibacterial Copper Delivery.
31534827 2019. Effect of Ionic Liquid Modification on the ORR Performance and Degradation Mechanism of Trimetallic PtNiMo/C Catalysts.
30221028 2018. Tuning the Electrocatalytic Performance of Ionic Liquid Modified Pt Catalysts for the Oxygen Reduction Reaction via Cationic Chain Engineering.
32123740 2020. Synthesis of Phospho-Amino Acid Analogues as Tissue Adhesive Cement Additives.
29632885 2018. Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis.
28386601 2017. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death.
25333917 2014. Reconstruction of cladoniamide biosynthesis reveals non-enzymatic routes to bisindole diversity.
22217014 2012. Inhibitors of Aminoglycoside Resistance Activated in Cells.
19278238 2009. Small Molecule Microarrays of RNA-Focused Peptoids Identifies Inhibitors of a Pathogenic Group I Intron RNA.
25695130 2015. A New Method To Image Heme-Fe Total Fe and Aggregated Protein Levels after Intracerebral Hemorrhage.
C7408243 2020. Ionic Liquid (1-Ethyl-3-methylimidazolium Acetate) Plasticization of Chitosan-Based Bionanocomposites.
32743155 2020. Waste-Printed Circuit Board Recycling: Focusing on Preparing Polymer Composites and Geopolymers.
32337441 2020. One-Pot Efficient Catalytic Oxidation for Bio-Vanillin Preparation and Carbon Isotope Analysis.
30613821 2018. Poly(glycerol sebacate)-Based Polyester–Polyether Copolymers and Their Semi-Interpenetrated Networks with Thermoplastic Poly(ester–ether) Elastomers: Preparation and Properties.
30411057 2018. iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with 68Ga and 64Cu: Unexpected Findings.
30087946 2018. Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY.
30023576 2017. Fluorescent and Photosensitizing Conjugates of Cell-Penetrating Peptide TAT(47-57): Design Microwave-Assisted Synthesis at 60 °C and Properties.
31457741 2017. Giant Enhancement of Carrier Mobility in Bimetallic Coordination Polymers.
31457533 2017. Low-Cost and High-Performance Hard Carbon Anode Materials for Sodium-Ion Batteries.
31457130 2016. Field-Induced Relaxation of Magnetization in a Three-Dimensional LnMOF with the Second Bridging Ligand Squarate.
29142789 2017. Catalytic Depolymerization of Lignin and Woody Biomass in Supercritical Ethanol: Influence of Reaction Temperature and Feedstock.
25548949 2015. EXPANSION OF BISINDOLE BIOSYNTHETIC PATHWAYS BY COMBINATORIAL CONSTRUCTION.
23656278 2012. Dimerization-Dependent Green and Yellow Fluorescent Proteins.
25328143 2015. Osteopontin is associated with inflammation and mortality in a mouse model of polymicrobial sepsis.
24773521 2014. Fatal injury caused by low-energy trauma – a 10-year rural cohort.
23284336 2012. Poly[aquaÂ(μ2-pyrimidine-2-carboxylÂato-κ4O N:O′ N′)(nitrato-κO)cadmium].
16511268 2006. Crystallization and preliminary X-ray diffraction analysis of a cold-adapted catalase from Vibrio salmonicida.
16508111 2005. Cloning preparation and preliminary crystallographic studies of penicillin V acylase autoproteolytic processing mutants.
18262230 2008. Hyalin is a Cell Adhesion Molecule Involved in Mediating Archenteron - Blastocoel Roof Attachment.
27708482 2016. Scientometric Dilemma: Is H-index Adequate for Scientific Validity of Academic’s Work?
25684846 2014. Factors Affecting Journal Quality Indicator in Scopus (SCImago Journal Rank) in Obstetrics and Gynecology Journals: a Longitudinal Study (1999-2013).
24825929 2014. Review of the Journal Acta Informatica Medica in 2013.
23572852 2013. Acta Informatica Medica Is Indexed In Pubmed And Archived In Pubmed Central.
23322957 2012. ON-LINE BIOMEDICAL DATABASES–THE BEST SOURCE FOR QUICK SEARCH OF THE SCIENTIFIC INFORMATION IN THE BIOMEDICINE.
27199537 2015. Imaging alterations in skeletal muscle channelopathies: a study in 15 patients.
22106717 2011. A novel N440K sodium channel mutation causes myotonia with exercise-induced weakness - exclusion of CLCN1 exon deletion/duplication by MLPA.
21314017 2010. State of the art in hereditary muscle channelopathies .
22029103 2010. Mendelian bases of myopathies cardiomyopathies and neuromyopathies.
29330575 2018. A new technique for minimal invasive complete spinal cord injury in minipigs.
26025657 2015. Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy.
22526019 2012. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
27461056 2016. Impact of increased risk for fetal aneuploidy on maternal mood: a prospective longitudinal study.
30669911 2019. Clinical significance of cervical MRI in brachial plexus birth injury.
22553905 2012. Correlation between radiographic measures of acetabular morphology with 3D femoral head coverage in patients with acetabular retroversion.
20450421 2010. Correction of axial and rotational alignment after medial and lateral releases during balanced gap TKA: A clinical study of 54 patients.
18283583 2008. Cellular matrix and growth factor components of the joint capsule are modified early in the process of posttraumatic contracture formation in a rabbit model.
24644412 2014. EDITORIAL.
24453635 2013. EDITORIAL.
C7252145 ä. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.
32528832 2020. Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease.
26579386 2014. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound baicalin.
20644551 2010. Ferulic acid inhibits nitric oxide-induced apoptosis by enhancing GABAB1 receptor expression in transient focal cerebral ischemia in rats.
23033877 2013. Organization of the neural switching circuitry underlying reflex micturition.
26590876 2016. Pilot randomised trial of a brief intervention for comorbid substance misuse in psychiatric inâ€patient settings.
25891484 2015. Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex.
23350770 2013. Childhood catatonia autism and psychosis past and present: is there an ‘iron triangle’?
22150101 2012. Making childhood catatonia visible separate from competing diagnoses.
17244171 2007. Melancholia: restoration in psychiatric classification recommended.
12956826 2003. Postmaturity in a genetic subtype of schizophrenia.
9395159 1997. A comprehensive method of assessing routine CT scans in schizophrenia.
17280565 2007. The doctrine of the two depressions in historical perspective.
30666066 2018. The First Fifty Years of Acta Stomatologica Croatica (1966 - 2016): Citation Analysis.
30804605 2017. ACTIVITY WORKFLOW IN THE PROCESS OF ARTICLE PUBLICATION AND QUALITY CONTROL IN THE JOURNAL ACTA STOMATOLOGICA CROATICA.
27789906 2016. Acta stomatologica Croatica and PubMed Central.
18471796 2008. High Prevalence of Entamoeba moshkovskii in a Tanzanian HIV population.
29109130 2017. Effects of electroacupuncture at BL33 on detrusor smooth muscle activity in a rat model of urinary retention.
31723931 2019. Acute and Critical Care will be indexed in PubMed PubMed Central Emerging Sources Citation Index and Scopus.
26774820 2016. Negative urgency mediates the relationship between childhood maltreatment and problems with alcohol and cannabis in late adolescence.
25452074 2015. Development and psychometric properties of the Social Smoking Situations (S3) Scale: An enhanced measure of social exposure to smoking during adolescence.
24290209 2014. The effects of acute exercise on tobacco cravings and withdrawal symptoms in temporary abstinent pregnant smokers☆.
24183303 2014. Moderators of the Association Between Peer and Target Adolescent Substance Use.
18760878 2008. Nicotine dependence symptoms among young never-smokers exposed to secondhand tobacco smoke.
28429843 2018. Pooled analysis of three randomized double-blind placebo controlled trials with rimonabant for smoking cessation.
28317210 2017. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: A respondent-driven sampling study.
24467265 2014. Association among different measures of alcohol use across adolescence and emerging adulthood.
24304295 2014. TESTING A SOCIAL ECOLOGICAL MODEL OF ALCOHOL USE: THE CALIFORNIA 50 CITY STUDY.
22296280 2012. Preferences for Evidence–Based Practice Dissemination in Addiction Agencies Serving Women: A Discrete–Choice Conjoint Experiment.
24977037 2012. Past Fame Present Frames and Future Flagship? An Exploration of How Health is Positioned in Canadian Foreign Policy.
23087490 2011. On the Nature and Strategies of Organized Interests in Health Care Policy Making.
28111591 2015. Delinquent behaviors among students exposed to family violence in Quebec schools.
28111592 2015. Health Outcomes of Sexual-Minority Youth in Canada: An Overview.
29177764 2018. ROCK and RHO Playlist for Preimplantation Development: Streaming to HIPPO Pathway and Apicobasal Polarity in the First Cell Differentiation.
23227044 2012. Do Peers See More in a Paper Than Its Authors?
20936175 2010. Designing Efficient Spaced Seeds for SOLiD Read Mapping.
20150956 2009. Synonymous Codon Usage Analysis of Thirty Two Mycobacteriophage Genomes.
26601093 2015. Potential risk factors associated with stress urinary incontinence among Iranian women.
24560216 2014. Comparison between the behavior of different hydrophobic peptides allowing membrane anchoring of proteins.
19233238 2009. Antioxidant Enzyme Gene Transfer for Ischemic Diseases.
28865027 2017. Drebrin and Spermatogenesis.
26002737 2015. Use of Chemical Auxiliaries to Control P450 Enzymes for Predictable Oxidations at Unactivated C–H Bonds of Substrates.
23955676 2014. Iatrogenic genetic damage of spermatozoa.
20384219 2010. Artificial Cell Microencapsulated Stem Cells in Regenerative Medicine Tissue Engineering and Cell Therapy.
29755309 2017. Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.
18688288 2007. Multifunctional hydrogels that promote osteogenic hMSC differentiation through stimulation and sequestering of BMP2.
28116565 2017. Pulling together and pulling apart: influences of convergence and divergence on distributed healthcare teams.
21318045 2011. Recent Advances in the Pathobiology of Hodgkin s Lymphoma: Potential Impact on Diagnostic Predictive and Therapeutic Strategies.
31172125 2019. Demography of Medical Journals in Iran; a Cross-Sectional Study.
32551324 2020. Effectiveness in Bowel Cleansing and Patient Tolerability of Polyethylene Glycol versus Sodium Picosulphate in Patients Undergoing Colonoscopy.
31886452 2018. The Psychological Science Accelerator: Advancing Psychology through a Distributed Collaborative Network.
30775689 2018. Writing Empirical Articles: Transparency Reproducibility Clarity and Memorability.
30971863 2018. Multi-domain Causal Structure Learning in Linear Systems.
18486688 2008. Strain Theory of Malaria: The First 50 Years.
21907908 2011. Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors.
21081213 2010. The Cardiovascular Physiology and Pharmacology of Endothelin-1.
31637168 2019. Single Molecule Magnetism with Strong Magnetic Anisotropy and Enhanced Dy∙∙∙Dy Coupling in Three Isomers of Dyâ€Oxide Clusterfullerene Dy2O@C82.
29938193 2018. A Nacreâ€Like Carbon Nanotube Sheet for High Performance Liâ€Polysulfide Batteries with High Sulfur Loading.
31192867 2019. Use of Thermal Imaging to Identify Deep-Tissue Pressure Injury on Admission Reduces Clinical and Financial Burdens of Hospital-Acquired Pressure Injuries.
22400020 2012. Neurogenic Bladder.
24761357 2014. Clinical Trials Involving Biphasic Pulsed Current MicroCurrent and/or Low-Intensity Direct Current.
C7148074 ä. Ranking Significant Discrepancies in Clinical Reports.
C7148057 ä. DSR: A Collection for the Evaluation of Graded Disease-Symptom Relations.
22238503 2011. Satellite Remote Sensing for Developing Time and Space Resolved Estimates of Ambient Particulate in Cleveland OH.
24309315 2011. Ionic channels as targets for drug design: a review on computational methods.
18693297 2008. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.
29921647 2018. Mechanisms and Drug Development in Atrial Fibrillation.
21079043 2010. Drug-induced long QT syndrome.
28720428 2017. Inhibitors of connexin and pannexin channels as potential therapeutics.
22274552 2012. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.
26660852 2016. KATP Channels in the Cardiovascular System.
32134952 2020. Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data.
25093754 2014. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
22087077 2011. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
30517121 2018. Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus.
27064990 2016. Relationship between QT Interval Length and Arterial Stiffness in Systemic Lupus Erythematosus (SLE): A Cross-Sectional Case-Control Study.
26296197 2015. Probucol-Induced alpha-Tocopherol Deficiency Protects Mice against Malaria Infection.
25793535 2015. Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.
24205103 2013. AfroDb: a select highly potent and diverse natural product library from African medicinal plants.
22493697 2012. Cholesterol depletion in adipocytes causes caveolae collapse concomitant with proteosomal degradation of cavin-2 in a switch-like fashion.
19771169 2009. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
27467575 2016. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
26086192 2015. Targeting Human Transmission Biology for Malaria Elimination.
15811881 2005. Acute poisoning: understanding 90% of cases in a nutshell.
11009581 2000. QT prolongation due to roxithromycin.
432163 1979. Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias.
19287558 2008. Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature.
10984545 2000. A common polymorphism associated with antibiotic-induced cardiac arrhythmia.
32425246 2020. Psychopharmacology of COVID-19.
31878817 2020. Acquired long QT syndrome in chronic kidney disease patients.
32409150 2020. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
32394513 2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
30858628 2019. Cardiac and vascular complications in rheumatoid arthritis.
30042604 2018. Antimalarials - are they effective and safe in rheumatic diseases?
32536565 2020. Living evidence in response to controversies about the use of antimalarials in COVID-19.
32493574 2020. COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity.
32638884 2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
31953740 2020. Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study.
22953235 2012. Emerging zoonoses: the "one health approach".
30532635 2018. Prevalence of Torsades de Pointes inducing drugs usage among elderly outpatients in North Jordan Hospitals.
19563673 2009. Management of the critically poisoned patient.
24981420 2014. Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells.
23953801 2013. Extracellular potassium homeostasis: insights from hypokalemic periodic paralysis.
25630313 2014. Importance of QT interval in clinical practice.
32528194 2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.
7787469 1995. Use of amiodarone in the postmyocardial infarction patient.
25083239 2012. Drug-induced QT interval prolongation: mechanisms and clinical management.
25165550 2013. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.
25165548 2013. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.
29201344 2017. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.
32368072 2020. Refractory Sarcoidosis: A Review.
30867824 2019. Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.
32418730 2020. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
32387694 2020. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
32387409 2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
32289548 2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.
32593867 2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
30794895 2019. Drug repurposing for new, efficient, broad spectrum antivirals.
32726238 2020. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
23675554 2013. Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management.
32621997 2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?
32621996 2020. HCQ induced QT prolongation- Primum non nocere.
32622993 2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.
32623080 2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.
32644224 2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
32643072 2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.
32645974 2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.
32648153 2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.
32647045 2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
32677113 2020. The cardiovascular effects of treatment with hydroxychloroquine and azithromycin.
32686633 2020. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.
32687267 2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.
32700555 2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
32726238 2020. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management. |
32762368 2020. Prolonged QT Interval in a Patient With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin.
32779770 2020. QTc prolongation during antiviral therapy in two COVID-19 patients. |
32780229 2020. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.
32782662 2020. Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID-19: Quantification and precautions for a busy clinician.
32789088 2020. Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review.
32817375 2020. Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
32827987 2020. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. |
32832735 2020. Prolongation of QT interval due to hydroxychloroquine overdose used in COVID-19 treatment.
32849949 2020. Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19. |
32853675 2020. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. |
32864627 2020. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.
32870576 2020. QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights.
32864768 2020. Reply to: "QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights".
32907357 2020. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation.
32918829 2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
32921678 2020. Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.
32936259 2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
32956782 2020. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
32956851 2020. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.
32958120 2020. Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.
32964535 2020. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
32964653 2020. Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic.
32971536 2020. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
33030660 2020. QTc interval prolongation, COVID-19 and chloroquine.
33032282 2020. Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.
33044166 2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.
33047848 2020. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
33059567 2020. Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19. |
33063447 2020. QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study.
33075484 2020. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. |
33077410 2020. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
33089050 2020. Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.
33098839 2020. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.
33102533 2020. QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment.
33132915 2020. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.
33154498 2020. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
33163895 2020. The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis. |
33164544 2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
33164789 2020. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
33173848 2020. Hydroxychloroquine and QT prolongation: reassuring data in approved indications.
33192602 2020. Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. |
33240503 2020. Electrical storm in a patient with COVID-19 treated with hydroxychloroquine: A case report.
33280207 2020. Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID-19.
33282067 2020. Electrocardiogrammes d un patient COVID-19 traite par l association hydroxychloroquine et azithromycine.
33291194 2020. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
33307378 2020. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
C7212241 2020. Hydroxychloroquine-associated QT interval prolongation.
C7237942 2020. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
C7289101 ?. QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019.
C7302795 2020. Bréve : Chloroquine OTC : danger !
C7303435 2020. Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report.
C7317079 2020. Hydroxychloroquine: QTc prolongation: case report.
C7320242 ?. Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint.
C7334107 2020. Azithromycin/hydroxychloroquine: QT prolongation with a notched broad T-wave following off-label therapy: case report.
C7334118 2020. Hydroxychloroquine: Corrected QT interval prolongation first degree atrioventricular block and left bundle branch block during an off-label treatment with hydroxychloroquine for COVID-19 pneumonia: 3 case reports.
C7334124 2020. Azithromycin/hydroxychloroquine/propofol: Hypoglycaemia and cardiotoxicities following off label use: 2 case reports.
C7334127 2020. Hydroxychloroquine: QTc prolongation following off-label-use: case report.
C7648208 2020. Hydroxychloroquine: Borderline prolongation of QTc interval during off-label treatment: case report.
C7648225 2020. Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports.
C7648240 2020. Hydroxychloroquine: QTc-prolongation following an off-label use: case report.
C7648244 2020. Hydroxychloroquine: QTc prolongation following off-label use: case report.
C7677429 2020. Azithromycin/hydroxychloroquine: Cardiac disorder followed by off-label use: case report.
C7677447 2020. Azithromycin/hydroxychloroquine: Torsade-de-pointes following off-label use: case report.
C7692421 2020. Azithromycin/hydroxychloroquine: Torsades-de-pointes following off label treatment: case report.
C7692436 2020. Hydroxychloroquine: Prolonged QTc interval following off-label use: case report.
C7717273 ?. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.
C7726269 2020. Ceftriaxone/hydroxychloroquine/tocilizumab: QT prolongation torsade-de-pointes and off label use: case report.
C7726274 2020. Azithromycin/hydroxychloroquine: Prolonged corrected QT following off label use: case report.
C7728508 2020. Hydroxychloroquine: Electrical storm and QT interval prolongation following off-label use: case report.
C7728516 2020. Chloroquine/erythromycin: QT interval prolongation and Torsade de Pointes: case report.
C7728522 2020. PRAC review confirms chloroquine- and hydroxychloroquine-related AEs.
C7654303 ?. HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.